Table 2.
Meta-analysis in patients with diabetic and antiretroviral toxic neuropathy
| ALC | Placebo | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Study | Baseline | Reduction | Reduction % | N | Baseline | Reduction | Reduction % | N | MD % (95% CI) |
| De Grandis, 2002 | – | −1.93±2.09 | −39.4±42.7 | 95 | – | −0.35±1.10 | −7.7±24.2 | 104 | −31.7 (−41.5; −21.9) |
| Sima UC, 2005 | 5.99±2.41 | −2.55±2.87 | −42.6±48.0 | 70 | 5.04±2.19 | −0.97±3.11 | −19.3±61.7 | 48 | −23.3 (−44.1; −2.5) |
| Sima UCE, 2005 | 5.69±2.69 | −2.17±3.46 | −38.2±60.8 | 58 | 5.32±2.60 | −1.45±2.75 | −27.3±51.7 | 61 | −11.0 (−31.3; 9.4) |
| Youle, 2007 | 6.16±2.26 | −1.32±1.84 | −21.4±29.9 | 43 | 6.17±1.81 | −0.61±1.55 | −9.9±25.1 | 44 | −11.5 (−23.2; 0.1) |
| Pooled analysis | 266 | 257 | −20.2 (−32.1; −8.3) | ||||||
Notes: Test for heterogeneity: τ2=88.58; χ2=8.06, df=3 (P=0.05); I2=62.8%. Test for overall effect: Z =3.32 (P<0.0001). Results are expressed as mean ± SD. Heterogeneity indexes: χ2, τ2, I2.
Abbreviation: ALC, acetyl-L-carnitine.